Profound Medical (TSE:PRN) Trading Down 2.9% - Should You Sell?

Key Points

• Price action: Profound Medical fell 2.9% to C$9.27 (intraday low C$9.14) on below-average volume, trading near its 200-day SMA of C$9.23 with a market cap of C$336.45 million.
• Mixed fundamentals: The company reported quarterly EPS of C$0.37 on C$8.0M revenue but shows a negative net margin (-248.45%) and negative ROE (-85.73%), while analysts forecast roughly -C$1.90 EPS for the fiscal year.
• Insider confidence: Director Dr. Arun Menawat purchased 20,000 shares at C$6.96, and corporate insiders now own 8.62% of the company.

Profound Medical Corp. (TSE:PRN - Get Free Report) traded down 2.9% during trading on Monday . The stock traded as low as C$9.14 and last traded at C$9.27. 9,809 shares changed hands during mid-day trading, a decline of 48% from the average session volume of 19,005 shares. The stock had previously closed at C$9.55.

Profound Medical Stock Down 2.9%

The company's 50 day simple moving average is C$8.78 and its 200-day simple moving average is C$9.23. The company has a current ratio of 12.52, a quick ratio of 14.98 and a debt-to-equity ratio of 7.09. The firm has a market cap of C$336.45 million, a P/E ratio of -6.57 and a beta of 1.07.

Profound Medical (TSE:PRN - Get Free Report) last announced its quarterly earnings results on Thursday, March 5th. The company reported C$0.37 EPS for the quarter. The firm had revenue of C$8.00 million during the quarter. Profound Medical had a negative net margin of 248.45% and a negative return on equity of 85.73%. Research analysts forecast that Profound Medical Corp. will post -1.9000001 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Dr. Arun Menawat bought 20,000 shares of the firm's stock in a transaction on Friday, March 20th. The stock was acquired at an average cost of C$6.96 per share, for a total transaction of C$139,200.00. Following the purchase, the director owned 658,660 shares in the company, valued at approximately C$4,584,273.60. This represents a 3.13% increase in their ownership of the stock. Corporate insiders own 8.62% of the company's stock.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.